Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 3 · 42.9%High 2 · 28.6%

Anti‐IL13 or anti‐IL4 agents vs placebo

Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma

Anti‐IL13 or anti‐IL4 agents probably leads to lower exacerbation requiring hospitalisation or ED visit compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
Rate ratio 0.68 [0.47, 0.98]
2 studies · 2039 participants
Moderate

Anti‐IL13 or anti‐IL4 agents vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 4960 participants
High

Anti‐IL13 or anti‐IL4 agents vs placebo

Serious adverse events · people with asthma

Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
OR 0.91 [0.76, 1.09]
22 studies · 7739 participants
Moderate

Anti‐IL13 or anti‐IL4 agents vs placebo

Rate of exacerbations requiring systemic corticosteroids · people with asthma

Anti‐IL13 or anti‐IL4 agents showed no clear difference in exacerbation requiring OCS (rate ratio) compared with placebo (low certainty).

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
RR 0.98 [0.72, 1.32]
1 study · 452 participants
Low

Anti‐IL13 or anti‐IL4 agents vs placebo

Change from baseline in ACQ score Scale: 0 to 6 (higher is worse) · people with asthma

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 6251 participants
Moderate

Anti‐IL13 or anti‐IL4 agents vs placebo

Adverse events (any) · people with asthma

Anti‐IL13 or anti‐IL4 agents leads to higher adverse events (any) compared with placebo (high certainty).

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
OR 1.16 [1.04, 1.3]
18 studies · 7419 participants
High

Anti‐IL13 or anti‐IL4 agents vs placebo

Time off work or study · people with asthma

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found